STOCK TITAN
  1. Home
  2. News
  3. ETON

Eton Pharmaceuticals Inc - ETON STOCK NEWS

Welcome to our dedicated news page for Eton Pharmaceuticals (Ticker: ETON), a resource for investors and traders seeking the latest updates and insights on Eton Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Eton Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Eton Pharmaceuticals's position in the market.

News
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
Rhea-AI Summary
Eton Pharmaceuticals acquires U.S. rights to PKU GOLIKE® from Relief Therapeutics, targeting the estimated $100 million U.S. PKU medical formula market. The transaction is expected to boost earnings in 2024, with estimated peak sales exceeding $10 million annually. PKU GOLIKE® is a next-generation medical formula designed to improve patient experience and adherence to strict PKU diets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.39%
Tags
acquisition
-
News
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Eton Pharmaceuticals reported a strong Q4 2023 with $7.3 million in revenue, a 109% increase from Q4 2022. Full-year 2023 revenues reached $31.6 million, driven by product sales and royalty revenues of $26.1 million, a 132% increase from 2022. Successful results from ET-400's pivotal bioequivalence study were announced, with an NDA submission planned for Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.68%
Tags
earnings
-
News
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
Rhea-AI Summary
Eton Pharmaceuticals, Inc. will report its fourth quarter and full year 2023 financial results on March 14, 2024. The management will host a conference call to discuss the results and answer questions from investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
conferences earnings
News
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
Rhea-AI Summary
Eton Pharmaceuticals secures US patent for ET-400 product candidate's formulation, expected to boost market exclusivity until 2043.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
none
-
News
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
Rhea-AI Summary
Eton Pharmaceuticals announces the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in the United States. The company offers a patient support program with $0 co-pay for eligible, commercially insured patients. Eton aims to capture a significant portion of the estimated $50 million annual Nitisinone market. The product is available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
-
News
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Eton Pharmaceuticals, Inc (ETON) reports a 118% increase in product sales and royalty revenue, reaching $7.0 million in the third quarter of 2023. The company also achieved positive cash flow from operations of $0.9 million and ended the quarter with $22.1 million in cash on hand. Additionally, Eton acquired the ultra-rare disease product Nitisinone Capsules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.23%
Tags
earnings
News
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
Rhea-AI Summary
Eton Pharmaceuticals, Inc. will report its third quarter 2023 financial results on November 9, 2023. The company focuses on developing, acquiring, and commercializing products for rare diseases. A conference call and live webcast will be held to discuss the results. Participants can also email questions to investorrelations@etonpharma.com. The webcast will be available on Eton's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
conferences earnings
-
News
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
Rhea-AI Summary
Eton Pharmaceuticals announces acquisition of Nitisinone Capsules and plans for Q1 2024 product launch. Nitisinone market estimated to be over $50 million annually. Eton Cares support program to be offered to all patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
acquisition
-
News
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Eton Pharmaceuticals to present at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
conferences
News
Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Eton Pharmaceuticals reports Q2 revenue of $12.0M and net income of $4.6M. Product sales and royalty revenue of $6.5M, up 175% YoY and 22% QoQ. Cash on hand is $21.6M. Betaine Anhydrous launched successfully. ET-400 on track for NDA submission in Q4 2023. Increased revenue expectation of $30M for this year. Strong growth prospects and goal of having 10 commercial rare disease products by end of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.08%
Tags
earnings
Stock ETON logo
Eton Pharmaceuticals Inc

Nasdaq:ETON

ETON Rankings

#4439 Ranked by Market Cap
#434 Ranked by Stock Gains
N/A Ranked by Dividends

ETON Stock Data

87.85M
19.90M
12.97%
27.94%
0.86%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Deer Park

About ETON

eton pharmaceuticals, inc. is a deer park, illinois-based pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the u.s. food and drug administration’s 505(b)(2) regulatory pathway. our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.